Xtant Medical Holdings (XMS) Q2 2026 Earnings Report

The call presents meaningful strategic and commercial progress — notably the Dilon distribution agreement, integration of 17 new sales reps, product launches (Trivium Shaped) and expanded TAM — which position Xtant for future growth. However, the quarter showed significant near-term financial deterioration: sharp year-over-year revenue decline, gross margin compression, a swing to a net loss and negative adjusted EBITDA, reduced cash balances and a modestly reduced full-year revenue guide. Many negative results are tied to one-time transitions (asset sales, license cessation, Dilon integration) and strategic investments, but the immediate financial metrics are weak while visibility into near-term cash/earnings recovery remains uncertain.

Xtant modestly lowered full‑year 2026 revenue guidance to $99 million–$103 million (from $101 million–$105 million previously), citing lower‑than‑expected biologics revenue in Q2 and persistent headwinds in its amnio line through the back half of the year; Q2 revenue was $23.0 million (vs. $35.4M GAAP / $24.8M pro forma in Q2 2025), gross margin was 57.9% (vs. 68.6% LY) and adjusted EBITDA was a loss of $2.7 million (vs. +$6.9M LY). Management stressed it still expects accelerating sequential biologics growth in H2 as the newly integrated Dilon team (17 reps + 2 regional managers) and an expanded field organization (now >25 reps and multiple national accounts) are fully deployed; HEMOBLAST contributed ~$1.5 million in Q2 (primarily recognized net—approximately $600k–$700k of additional revenue would have been recognized if shipped under Xtant POs), and the company continues to model HEMOBLAST transactional volume at over $1 million per month on a gross basis once transitions complete.